Epilepsy News and Research

Latest Epilepsy News and Research

Neurological Institute at University Hospitals receives Neuroscience Center of Excellence designation

The Neurological Institute at University Hospitals has been designated as a Neuroscience Center of Excellence (COE), according to the Neuroscience Center of Excellence Survey sponsored by NeuStrategy, Inc., Chicago. It is the first neurological program in Ohio to receive the Stage 4 - Institute designation.

27 May 2010

Weill Cornell Medical College commences construction of 18-story, $650 million Medical Research Building

Weill Cornell Medical College today celebrated the start of construction on its new Medical Research Building, a state-of-the-art facility that will more than double the institution's existing research space. The 18-story, $650 million building is the centerpiece of Weill Cornell's $1.3 billion Discoveries that Make a Difference Campaign, the country's largest for a medical college. A total of $1 billion has been raised toward this goal in a record time of less than four years.

27 May 2010

Vertex reports 75% patients with HCV achieve viral cure with 12-week telaprevir-based combination regimen

Vertex Pharmaceuticals Incorporated today announced that 75% of people chronically infected with genotype 1 hepatitis C virus (HCV) who had not previously been treated achieved a sustained viral response (SVR or viral cure) after receiving a 12-week telaprevir-based combination regimen, followed by treatment with pegylated-interferon and ribavirin alone, in the Phase 3 ADVANCE trial.

26 May 2010

Ortho-McNeil Pharmaceutical pleads guilty for promoting epilepsy drug Topamax for psychiatric use

Ortho-McNeil Pharmaceutical LLC, a subsidiary of Johnson & Johnson, pled guilty today in U.S. District Court in Boston to one count of misdemeanor violation of the Food, Drug & Cosmetic Act for illegally promoting its epilepsy drug Topamax for uses that were not approved by the FDA. The company was also sentenced at today's hearing.

24 May 2010

NeuroTherapeutics Pharma closes $43 million Series B financing round

NeuroTherapeutics Pharma, Inc. (NTP), a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders, announced today that it closed a $43 million Series B financing. New investors include Fidelity Biosciences, MPM Capital and SR One, who co-led the transaction, and Pfizer, Inc. Existing investors Novo Ventures and Thomas McNerney & Partners also participated in the round.

20 May 2010

Research shows improved treatment of severe epilepsy reduces overall cost of the condition

Improved treatment of severe epilepsy could reduce the overall cost of the condition, according to research presented at the annual meeting of the International Society of Pharmacoeconomic Outcomes Research at the Hilton Atlanta in Atlanta, Georgia.

20 May 2010

Children with new/recent onset epilepsy have slowed expansion of white matter volume

A newly published study reported that children with new/recent onset epilepsy have significantly slowed expansion of white matter volume compared to healthy children over a two year interval. The reduced white matter volume may affect brain connectivity and influence cognition. Results of this study conducted by researchers from the University of Wisconsin School of Medicine and Public Health are now available online and will appear in the July issue of Epilepsia, a journal published by Wiley-Blackwell on behalf of the International League Against Epilepsy.

19 May 2010

Studies suggest potent therapeutic effects of rufinamide in bipolar disorder, depressive and anxiety disorders

This study formulates the hypothesis that rufinamide, a drug so far used against epilepsy, may also be effective in bipolar disorder, depressive and anxiety disorders, panic disorder and obsessive-compulsive disorder, eating disorders, and substance use disorders. It is just an hypothesis based on two cases that needs to be confirmed by specific studies.

19 May 2010

Third International Epilepsy Colloquium to be hosted in Cleveland

About 200 epilepsy specialists, neurosurgeons and pediatric neurologists from around the nation and the world are registered to attend the Third International Epilepsy Colloquium in Cleveland from May 19 to 22. The conference is sponsored by the Neurological Institute at University Hospitals Case Medical Center and Case Western Reserve University School of Medicine.

19 May 2010

Catalyst Pharmaceutical Partners first-quarter net loss decreases to $0.06 per basic and diluted share

Catalyst Pharmaceutical Partners, Inc. today announced its financial results for the three month period ended March 31, 2010. The Company reported a net loss of $1,045,043, or $0.06 per basic and diluted share, compared to a net loss of $3,031,201, or $0.22 per basic and diluted share, for the same period in 2009.

18 May 2010

High-fat ketogenic diet effective in treating infantile spasms

The high-fat ketogenic diet can dramatically reduce or completely eliminate debilitating seizures in most children with infantile spasms, whose seizures persist despite medication, according to a Johns Hopkins Children's Center study published online April 30 in the journal Epilepsia.

18 May 2010

Altered blood flow leads to falls in elderly people: Research

A new study shows that altered blood flow in the brain due to high blood pressure and other conditions may lead to falls in elderly people. The research will be published in the May 18, 2010, issue of Neurology, the medical journal of the American Academy of Neurology. Each year, unintentional falls in the United States account for more than 16,000 deaths and 1.8 million emergency room visits.

18 May 2010

Mechanism in newborn's memory centre that adjusts brain maturation for information processing discovered

With their French colleagues, researchers at the University of Helsinki have found a mechanism in the memory centre of newborn that adjusts the maturation of the brain for the information processing required later in life. The study was published this week in an American science magazine The Journal of Neuroscience.

15 May 2010

Children with epilepsy say their quality of life is comparable to that of healthy siblings

Children with epilepsy often face multiple challenges - not only seizures but learning, cognitive and school difficulties, side effects from medication, and, not surprisingly, social stigma from their peers.

14 May 2010

Neurologix reports lower net loss of $3.5M for first-quarter 2010

Neurologix, Inc., a biotechnology company developing innovative gene therapies for the brain and central nervous system, today announced its financial results for the quarter ended March 31, 2010.

14 May 2010

Mutations in STRAD-alpha gene can cause PMSE syndrome in Amish children: Penn researchers

So often the rare informs the common. Penn researchers investigating a regulatory protein involved in a rare genetic disease have shown that it may be related to epileptic and autistic symptoms in other more common neurological disorders.

12 May 2010

Iowa researcher uses new technique to verify brain's master switch

The protein that has long been suspected by scientists of being the master switch allowing brains to function has now been verified by an Iowa State University researcher.

10 May 2010

Icagen reports revenues of $1.5M, net loss of $3.2M for first-quarter 2010

Icagen, Inc. reported today its financial results and operational highlights for the first quarter ended March 31, 2010. For the first quarter of 2010, the Company reported revenues of $1.5 million and a net loss of $3.2 million. As of March 31, 2010, the Company's cash and cash equivalents totaled $14.3 million.

7 May 2010

Survey reveals low awareness of postherpetic neuralgia amongst Americans

The American Pain Foundation (APF) announced today at the American Pain Society (APS) Annual Meeting the results of a national survey that showed postherpetic neuralgia (PHN), also known as after-shingles pain, continues to be a condition with low awareness amongst Americans, demonstrating a need for health care provider (HCP) intervention.

7 May 2010

Keryx Biopharmaceuticals commences Phase 3 registration program for Zerenex

Keryx Biopharmaceuticals, Inc. announced today the initiation of its short-term Phase 3 study of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis.

6 May 2010

Epilepsy News and Research

Latest Epilepsy News and Research

Neurological Institute at University Hospitals receives Neuroscience Center of Excellence designation

Weill Cornell Medical College commences construction of 18-story, $650 million Medical Research Building

Vertex reports 75% patients with HCV achieve viral cure with 12-week telaprevir-based combination regimen

Ortho-McNeil Pharmaceutical pleads guilty for promoting epilepsy drug Topamax for psychiatric use

NeuroTherapeutics Pharma closes $43 million Series B financing round

Research shows improved treatment of severe epilepsy reduces overall cost of the condition

Children with new/recent onset epilepsy have slowed expansion of white matter volume

Studies suggest potent therapeutic effects of rufinamide in bipolar disorder, depressive and anxiety disorders

Third International Epilepsy Colloquium to be hosted in Cleveland

Catalyst Pharmaceutical Partners first-quarter net loss decreases to $0.06 per basic and diluted share

High-fat ketogenic diet effective in treating infantile spasms

Altered blood flow leads to falls in elderly people: Research

Mechanism in newborn's memory centre that adjusts brain maturation for information processing discovered

Children with epilepsy say their quality of life is comparable to that of healthy siblings

Neurologix reports lower net loss of $3.5M for first-quarter 2010

Mutations in STRAD-alpha gene can cause PMSE syndrome in Amish children: Penn researchers

Iowa researcher uses new technique to verify brain's master switch

Icagen reports revenues of $1.5M, net loss of $3.2M for first-quarter 2010

Survey reveals low awareness of postherpetic neuralgia amongst Americans

Keryx Biopharmaceuticals commences Phase 3 registration program for Zerenex

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Epilepsy News and Research

Latest Epilepsy News and Research

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in